MedTrace Logo

Pulmonary Hypertension, Hypoxia and Sickle Cell Disease

NCT00495638 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2019-12-16

No results posted yet for this study

Summary

The study will look at the risk factors for pulmonary hypertension (high blood pressure in the lungs) in children and adolescents with sickle cell anemia (SCA) and examine the role of hypoxia (oxygen shortage) in the disease. In patients with SCA, red blood cells become sickle-shaped and tend to form clumps that get stuck in blood vessels, blocking blood flow to the limbs and organs. Blocked blood vessels can cause pain, serious infections, and organ damage. Many patients with SCA also develop pulmonary hypertension.

Children and adolescents with SCA or Chuvash polycythemia (another blood disorder that carries an increased risk for pulmonary hypertension) may be eligible for this study.

Participants undergo the following procedures at the beginning (baseline) and end of the study:

* History, physical examination and blood tests .
* Echocardiography (ultrasound study of heart function).
* Transcranial doppler (brain ultrasound study to measure brain blood flow).
* Lung function tests.
* 6-minute walk (measure of the distance covered in 6 minutes of walking).

In addition, patients are followed by telephone or by clinic visits every 6 months for a review of their medical history and medications. A physical examination is also done at 12 months.

Conditions

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Caterina P Minniti, M.D. · National Heart, Lung, and Blood Institute (NHLBI)

Eligibility

Min Age
3 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-28
Completion
2014-12-02

Countries

  • United States
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00495638 on ClinicalTrials.gov